Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Rated "Moderate Buy" by Sell-Side Brokerages

Cogent Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts rate Cogent Biosciences a “Moderate Buy”: Six of nine covering firms recommend buying, one strongly recommends buying, one rates it hold, and one recommends selling. The average 12-month price target is $53.57.
  • Several firms raised or maintained price targets in the $52–$56 range, while the stock opened at $27.74 and was near its 52-week low of $26.36.
  • Cogent reported a quarterly loss of $0.59 per share, missing the consensus estimate of a $0.56 loss; analysts expect a full-year loss of $2.37 per share.
  • MarketBeat previews the top five stocks to own by December 1st.

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $53.57.

COGT has been the subject of a number of research analyst reports. Piper Sandler boosted their target price on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an "overweight" rating in a research report on Monday, August 17th. Wall Street Zen lowered Cogent Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, September 5th. Wedbush reiterated an "outperform" rating and issued a $55.00 price objective on shares of Cogent Biosciences in a research report on Wednesday, September 16th. Guggenheim boosted their price target on shares of Cogent Biosciences from $45.00 to $52.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Finally, HC Wainwright raised their target price on Cogent Biosciences from $55.00 to $56.00 and gave the stock a "buy" rating in a report on Monday, November 9th.

View Our Latest Stock Report on Cogent Biosciences

Institutional Trading of Cogent Biosciences

Institutional investors have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Cogent Biosciences by 26.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 209,402 shares of the technology company's stock valued at $8,104,000 after purchasing an additional 43,892 shares in the last quarter. Sculptor Capital LP acquired a new stake in Cogent Biosciences during the 2nd quarter worth approximately $1,935,000. Wellington Management Group LLP boosted its position in shares of Cogent Biosciences by 21.4% in the second quarter. Wellington Management Group LLP now owns 4,343,977 shares of the technology company's stock valued at $168,112,000 after acquiring an additional 765,355 shares during the period. Legal & General Group Plc bought a new position in Cogent Biosciences during the 2nd quarter worth $3,824,000. Finally, Weiss Asset Management LP bought a new stake in Cogent Biosciences during the first quarter worth $13,322,000.

Cogent Biosciences Trading Down 0.3%

NASDAQ COGT opened at $27.74 on Friday. The company has a market capitalization of $4.83 billion, a PE ratio of -12.33 and a beta of 0.36. The company has a current ratio of 10.99, a quick ratio of 10.99 and a debt-to-equity ratio of 0.50. Cogent Biosciences has a 1-year low of $26.36 and a 1-year high of $43.73. The firm's fifty day simple moving average is $30.84 and its 200-day simple moving average is $35.12.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The technology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03). As a group, sell-side analysts anticipate that Cogent Biosciences will post -2.37 earnings per share for the current fiscal year.

Cogent Biosciences Company Profile

(Get Free Report)

Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company's lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.

See Also

Analyst Recommendations for Cogent Biosciences (NASDAQ:COGT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cogent Biosciences Right Now?

Before you consider Cogent Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.

While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines